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A Health Economics Approach to US Value Assessment Frameworks: Summary and Recommendations of 
the ISPOR Special Task Force Report  
 
Abstract 
  
This summary paper first lists key points from each of the six sections, followed by six key 
recommendations. The Special Task Force chose take a health economics approach to the question of 
whether a health plan should cover and reimburse a specific technology, beginning with the view that 
the conventional cost per quality-adjusted life year (QALY) metric has both strengths as a starting point 
and recognized limitations.  This report calls for the development of a more comprehensive economic 
evaluation that could include novel elements of value (e.g., insurance value, equity) either as part of an 
 “ĂƵŐŵĞŶƚĞĚ ?ĐŽƐƚ-effectiveness analysis or a multi-criteria decision analysis.  Given an aggregation of 
elements to a measure of value, consistent use of a cost-effectiveness threshold can help assure the 
maximization of health gain and well-being for a given budget.  These decisions can benefit from the use 
of deliberative processes.  The six recommendations are to: (I) Be explicit about decision context and 
perspective in value assessment frameworks; (II) Base health plan coverage and reimbursement 
decisions on an evaluation of the incremental costs and benefits of healthcare technologies as is 
provided by cost-effectiveness analysis; (III) Develop value thresholds to serve as one important input to 
help guide coverage and reimbursement decisions; (IV) Manage budget constraints and affordability 
based on cost-effectiveness principles; (V) Test and consider using structured deliberative processes for 
health plan coverage and reimbursement decisions; (VI) Explore and test novel elements of benefit to 
improve value measures that reflect the perspectives of both plan members and patients.  
 
 
Preamble:   
 
ƵƌŝŶŐƚŚĞĐŽƵƌƐĞŽĨƚŚĞ^d& ?ƐǁŽƌŬ ?ǁĞŝŶǀŝƚĞĚĞǆƚĞƌŶĂůŝŶƉƵƚŽŶƚwo earlier versions of draft reports.  A 
ĨŝƌƐƚĚƌĂĨƚƌĞƉŽƌƚǁĂƐƐĞŶƚƚŽƚŚĞ^d& ?ƐǆƚĞƌŶĂůĚǀŝƐŽƌǇŽĂƌĚĂŶĚ^ƚĂŬĞŚŽůĚĞƌĚǀŝƐŽƌǇ'ƌŽƵƉŽŶDĂǇ
4, 2017.  In response to feedback received, we posted a revised version to the full ISPOR membership on 
July 7, 2017.   
 
These efforts resulted in many thoughtful and often detailed comments from a wide range of individuals 
representing diverse stakeholders, including patient organizations, payers, academic researchers, and 
the pharmaceutical and medical device industries.  The STF greatly appreciates this input and the final 
report is much improved because of it.  We begin this final section with a summary of what we heard 
and how we responded. 
 
Some reviewers praised the tenor and scope of the report and recommendations.  Some underlined 
generally the need for more emphasis on transparency and stakeholder input into value framework 
methods and processes.  
 
Many reviewers offered constructive criticism.  A number emphasized that the report should be more 
 “ƉĂƚŝĞŶƚ-ĐĞŶƚƌŝĐ ? ?^ƉĞĐŝĨŝĐĂůůǇ ?ƚŚĞǇĞŵƉŚĂƐŝǌĞĚƚŚĂƚƚŚĞƉĂƚŝĞŶƚƉĞƌƐƉĞĐƚŝǀĞĂŶĚƉĂƚŝĞŶƚǀŽŝĐĞŶĞĞĚĞĚƚŽ
be reflected in all discussions about value ? for example, that value measurement should consider 
ƉĂƚŝĞŶƚƐ ?ƉĞƌƐŽŶĂůŐŽĂůƐĂŶĚƉƌĞĨĞƌĞŶĐĞƐĨŽƌĚŝĨĨĞƌĞŶƚƌĞĂƚŵĞŶƚŽƉƚŝŽŶƐ ? 
 
Some commenters highlighted the shortcomings of the quality-adjusted life year (QALY) metric, noting 
that QALYs often do not capture patient preferences well and potentially discount the value of an 
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ŝŶĚŝǀŝĚƵĂů ?ƐĚŝƐĂďŝůŝƚǇ ?EƵŵĞƌŽƵƐƌĞǀŝĞǁĞƌƐĂĚĚƌĞƐƐĞĚƚŚĞ^d& ?ƐƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐregarding the use of 
cost-per-QALY metrics to inform public and private decision making.  Some spoke in favor of this 
recommendation, though others cautioned that such use could impede access to important new 
treatments, and, more generally, argued that any overarching STF recommendations calling for payers 
to apply cost-per-QALY analyses and cost-effectiveness thresholds was not consonant with the 
pluralistic, market-ďĂƐĞĚh ?^ ?ŚĞĂůƚŚƐǇƐƚĞŵ ?^ŽŵĞƉŽŝŶƚĞĚŽƵƚƚŚĞh^ŐŽǀĞƌŶŵĞŶƚ ?ƐŽǁŶƌĞƐƚƌŝĐƚŝŽŶƐ
on use of cost-per-Y>zƚŚƌĞƐŚŽůĚƐĂƐĞǀŝĚĞŶĐĞŽĨƚŚĞŵĞƚƌŝĐ ?ƐůŝŵŝƚĂƚŝŽŶƐĂŶĚƉƵďůŝĐŽƉƉŽƐŝƚŝŽŶ ? 
 
The STF considered each comment carefully as we revised the report, mindful of the diverse 
ŵĞŵďĞƌƐŚŝƉŽĨ/^WKZĂŶĚƚŚĞŽƌŐĂŶŝǌĂƚŝŽŶ ?ƐŵŝƐƐŝŽŶƚŽĂĚǀĂŶĐĞŐŽŽĚŵĞƚŚŽĚƐĂŶĚŝŶĨŽƌŵĞĚĚĞĐŝƐŝŽŶ
making in pharmacoeconomics and outcomes research.  Compared to earlier drafts, the final report 
contains more text on the importance of patient centricity, for example.  In numerous places, we 
qualified language in response to feedback.  We recognize that given the varied opinions of ISPOR 
members, not everyone will be satisfied with our judgments.  Inviting the external commentaries that 
accompany the formal publication of this effort is one further attempt to ensure that diverse views are 
aired. The larger conversation about value metrics will undoubtedly continue on many fronts. 
 
This summary section presents a list of key points from each of the six sections of our report, followed 
by a section listing our six key recommendations [1-6].  It is important to note that this report reviewed 
five recent US value assessment frameworks that differ by perspective and decision context.  From a 
health economics perspective, the primary focus of our recommendations is on US payers ? private and 
public.  Broadly, our Special Task Force recommends greater use of cost-effectiveness analysis (CEA) in 
their decision making in order for them to best serve the interests of the plan members and patients 
who they represent.  We also recognize, however, that there are challenges in applying CEA as well as a 
need for more research on the elements of value, on their aggregation, and on how they are used in 
deliberative decision making. 
 
7.1 Section 1ͶIntroduction [1] 
 
x Concerns about rising prescription drug prices have led to initiatives in the U.S. designed to measure 
and communicate the value of pharmaceuticals. 
x Organizations promulgating value assessment frameworks differ in their missions, activities, and 
approaches. 
x This paper is based on the premise that value-based resource allocation decisions ? about drugs and 
other healthcare technologies ? should consider the full costs and benefits of decisions to relevant 
stakeholders and the decision contexts they face. 
x We define  “value ? from an economic perspective ŝŶƚǁŽƌĞůĂƚĞĚ ?ďƵƚĚŝƐƚŝŶĐƚƐĞŶƐĞƐ P “gƌŽƐƐǀĂůƵĞ ?ŝƐ 
what individuals (or others acting on their behalf) would be willing to pay to acquire more health 
care or other goods or services. This has to be compared with ƚŚĞ “ŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚ ?ŝŶƚĞƌŵƐŽĨ
what benefits or other resources they are willing to forgo to obtain them.  The difference between 
the two is ƚŚĞ “ŶĞƚǀĂůƵĞ ? ? 
x Rewarding healthcare technology manufacturers based on value is important because it sends 
signals to them that can influence R&D and ultimately innovation. 
x Health economists have long recommended that analysts seeking to inform resource allocation 
decisions approximate ĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐǀĂůƵĞin terms of incremental cost per QALYs gained (or the 
similar disability-adjusted life year (DALY) used commonly in global health evaluations). 
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x QALYs may not always fully capture the health (or well-being) of patients, or incorporate individual 
or community preferences about the weight to be given to health gain ? e.g., about disease severity, 
equity of access, or unmet need. 
 
7.2 Section 2Ͷ An Overview of Value, Perspective, and Decision Context [2] 
 
x Because individuals vary in terms of their preferences for health care versus other goods, partly due 
to varying incomes, and in terms of their preferences for different health outcomes (e.g., survival vs. 
quality of life), for any specific health care technology, there would be a distribution of valuations in 
a population. 
x Insurers ? both private and public ? act as agents on behalf of their enrollees who are potential 
patients by obtaining or providing access to healthcare technologies. 
x Given that most medical care is purchased indirectly via health insurance, individuals do not directly 
face prices, and their agents (insurers and providers) acting on their behalf must assess value. 
x CEA ?ďǇƌĞůĂƚŝŶŐĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ?ƐĐŽƐƚƚŽŝƚƐĞĨĨĞĐƚŝǀĞŶ ƐƐ ?/ŶƚĞƌŵƐŽĨƐŽŵĞĐŚĂŶŐĞŝŶŚĞĂůƚŚ ?in a 
ratio is thus a standard approach to measuring the net value of a healthcare intervention. 
x Existing guidelines for CEA emphasize the importance of clearly specifying the perspective from 
which the analysis is undertaken.  Relevant perspectives may include among others: (i) the typical 
health plan enrollee; (ii) the patient; (iii) health plan manager; (iv) the provider; (v) the technology 
manufacturer; (vi) the specialty society; (vii) government regulators, or (viii) society as a whole.  A 
valid and informative CEA could be conducted from the perspective of any of these stakeholders, 
depending on the purpose of the analysis.   
x The five recent value frameworks that motivated this Special Task Force vary in the decisions that 
are being informed by the valuation, ranging from coverage, access, and pricing, to defining 
appropriate clinical pathways, and to supporting provider-clinician shared decision making. 
x This economic concept of value does not depend on whether value is being measured within a 
market-based or a single-payer health care system.  Health economics and outcomes researchers 
generally measure value using the tool of CEA with the QALY as the heath gain measure.  
x Information about value is, however, used differently in different types of health care systems and 
by different stakeholders in different decision contexts. 
x Payers may wish to use valuation by CEA to support coverage decisions as well as negotiations with 
ŵĂŶƵĨĂĐƚƵƌĞƌƐŽǀĞƌĂ “ǀĂůƵĞ-ďĂƐĞĚƉƌŝĐĞ ? ? A health economics approach is most relevant to this 
decision context, and thus is the focus of this report. 
x Specialty societies (such as ACC) or other organizations (such as NCCN or ASCO) may use CEA or 
other value frameworks to design appropriate clinical pathways or to support shared clinical 
decision making. 
x Each of these value frameworks must be evaluated in its own decision context for its own 
objectives. 
x In market-based systems, the individual ? wearing the two hats of the patient and the plan enrollee 
(i.e., a potential patient) ? tends to be the ultimate decision maker, but individuals make these 
decisions with the assistance of agents ? the insurer and providers.   
x CEA can be patient-centric in that valuation can consider the impact of specific disease attributes on 
patientƐ ? length of survival and quality of life. 
x In a market-based system, decision making is more decentralized.  Consumers making decisions 
about the purchase of private health insurance or out-of-pocket spending may vary in their  
objectives and preferences.  Thus, they will choose among different health plans that will have 
different willingness to pay for QALYs and so different cost-effectiveness thresholds.  
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7.3 Section 3--Defining Elements of Value in Health Care [3] 
 
x The underlying concept of value from a health economic perspective is typically measured using 
CEA.  The cost-effectiveness of a medical technology is always calculated relative to alternative 
choices.  For this reason, CEA focuses on incremental costs and incremental benefits.  
x As recommended by the Second Panel, a wide range of costs or cost savings ? present and future ?
should be considered, so long as they result directly from the interventions of interest. 
x Benefit is measured from the perspective of the patient (or potential patient) given the healthcare 
technology in question.  Ideally, we would have some way of capturing all these changes in terms of 
a common unit.   
x To solve this problem, health economistƐŚĂǀĞĚĞǀĞůŽƉĞĚƚŚĞĐŽŶĐĞƉƚŽĨĂ “ƋƵĂůŝƚǇ-adjusted life-
ǇĞĂƌ ? ?Y>z ? ?ǁŚŝĐŚĐĂŶŝŶƉƌŝŶĐŝƉůĞďĞƵƐĞĚƚŽŵĞĂƐƵƌĞƚŚĞŚĞĂůƚŚďĞŶĞĨŝƚŽĨĂŶǇƚĞĐŚŶŽůŽŐǇ ?
regardless of the disease it treats. 
x QALYs and costs often form the basis of value assessments based on CEA. However, QALYs capture 
only a subset of benefits that may be produced by a health care intervention. This framework 
neglects numerous alternative aspects of benefits that should also be considered. 
 
 
x Despite its challenges, the QALY remains the most accepted measure for capturing the incremental 
benefit of a treatment for use in population-level decision-making. However, some additional 
elements that may reflect value but are not normally captured in CEA with the QALY should be 
considered as well, depending on the perspective of the analysis.  
x Productivity gains, net of consumption, should be included for societal-level perspectives, in the 
incremental cost calculations for CEA. 
x Best practice for CEA measurement includes capturing the effects (on both outcomes and costs) of 
real world behavior such as adherence to an intervention.   
x Some value elements, such as the value of knowing as part of diagnosis, or the psychic fear of 
contagion, are generally not captured but should be considered when relevant. 
x Other value elements including value of insurance, severity of disease, value of hope, and real 
option value have been shown to modify QALY estimates, but are not commonly used in CEA 
Further research to evaluate their potential for more standard use is warranted.  
x Two other potential value elements ? equity (beyond severity effects discussed above) and scientific 
spillover effects ? may have both individual and societal implications; more research on how to 
measure and incorporate these elements is also suggested. 
x Augmenting CEA to consider these additional elements would result in a more comprehensive CEA 
ŝŶůŝŶĞǁŝƚŚƚŚĞ^ĞĐŽŶĚWĂŶĞů ?Ɛ/ŵƉĂĐƚ/ŶǀĞŶƚŽƌǇ ? 
x More research and experience are needed in the application of augmented CEA (ACEA) and the 
Impact Inventory.  To the extent that additional elements can be valued in monetary terms, the 
evaluation more closely resembles a CBA (cost-benefit analysis), which is sometimes ƚĞƌŵĞĚ “ŶĞƚ
ŵŽŶĞƚĂƌǇďĞŶĞĨŝƚ ? ?ED ? ? 
 
7. 4 Section 4ͶObjectives, Budgets, Thresholds and Opportunity Costs  
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x Use of value assessment frameworks for coverage and pricing decisions ideally requires a decision 
rule about what constitutes good value for money. Consistent use of a cost-effectiveness threshold, 
with potential consideration of other elements, can help assure the maximization of health gain 
(e.g., QALYs), for a given budget.  
x The choice of a threshold hinges on the decision-ŵĂŬĞƌ ?ƐďƵĚŐĞƚ ?ŐŝǀĞŶƚŚĞĚŝƐƚƌŝďƵƚŝŽŶŽĨŚĞĂůƚŚ 
care technologies:  the higher the threshold, the larger must be the budget to accommodate all 
technologies that meet that threshold.  In a health care system with a fixed budget, in the short run, 
the threshold should reflect the opportunity cost of the technologies displaced when new 
technologies are introduced. 
x Thresholds and budgets used to make coverage decisions from a payer perspective, should ? to the 
extent possible ?ƌĞĨůĞĐƚĐŽŶƐƵŵĞƌƐ ? ?ƚĂǆƉĂǇĞƌƐ ?tdWĨŽƌŚĞĂůƚŚĂŶĚĨŝŶĂŶĐŝĂůƉƌŽƚĞĐƚŝŽŶex ante, i.e., 
preferences for insurance before individuals require health care.   
x We do not recommend considering budget impact as an integral part of value assessment itself or 
structuring/requiring an automatic discount linked to budget impact, or introducing an inverse 
relationship between value and budget impact.   
x Even where decision makers operate with an explicit threshold or threshold range, a deliberative 
process is generally followed to allow for external considerations that may modify the choice of 
threshold, such as equity or end-of-life concerns.  
 
 
 
7. 5 Section 5ͶApproaches to Aggregation and Decision Making 
 
x While conventional CEA and CBA are the gold standards for combining components of value and 
cost into a single metric, they have limitations in terms of how they address aggregation across 
individuals (incorporating equity, fairness, disparities, and other criteria), and in practice they do 
not incorporate some important components of value and cost.  
x Extended CEA (ECEA) is a method for evaluating the distributional effects on financial risk of a 
medical intervention on a set of population subgroups of interest. However, by creating separate 
measures of health gain and financial risk, it does not provide a single metric for treatment 
evaluation. 
x Augmented CEA (ACEA) is a proposed method for including novel elements of value in treatment 
evaluation. It may be expressed as a multi-dimensional inventory of effects, as a cost-effectiveness 
ratio with additional elements included in both cost and utility, or as net monetary benefit. More 
research and testing is needed before this approach can be incorporated in decision making. 
x Public and private insurers use deliberative decision making for payer coverage and reimbursement 
decisions. This can be improved, both by the introduction of cost-per-QALY evidence and by the use 
of more structured decision making to take account of preferences about the weight to be given to 
health gain compared to other attributes such as disease severity, equity of access, or unmet need.  
x A transparent deliberative process can also increase the legitimacy of decision making.  Currently, 
processes often lack transparency, and it is unclear what factors have been considered and how 
decisions were reached.  Deliberative processes today are often informal and unstructured. Thus, 
without a standardized approach, key issues may be overlooked, decisions may be reached in an 
unstandardized way, and potential biases of decision makers may not be adequately explored.  
x Multi-criteria decision analysis (MCDA) provides a constructive approach to inform decision making 
about value, but its theory, application, and implementation need additional research. 
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Novel methods for acquiring value weights, particularly in settings with committees acting as 
decision-makers, may hold promise. 
 
7.6 Section 6 - Review of Recent U.S. Value Frameworks 
x The recently proposed US value frameworks can be characterized in terms of their decision contexts 
and perspectives, which determine how each accounts for costs and outcomes. 
x The frameworks show substantial diversity in how they define and measure value, ranging from CEA 
to shared decision making by clinicians and patients. 
x While the frameworks have contributed in important ways to debates about value, they have been 
criticized on various grounds, for example, lacking conceptual foundation, omitting key components 
of cost or outcome given their perspectives, and not correctly considering uncertainty. 
x Recent frameworks also vary considerably in whether and how they handle decision thresholds, 
equity, and budget concerns; our report provides some suggestions in these areas. 
x Ideally, plan-level decisions would also incorporate individual and patient heterogeneity in 
outcomes, for example through sub-group analysis; while recent plan-level frameworks discuss 
these considerations, room for improvement remains. 
x Patient-oriented value frameworks can play a useful role within health plans by, for example 
informing patients about the relative benefits and costs of therapies given different copayments.  
Allowing consumer choice across plans can help accommodate heterogeneity in preferences. 
x There are many potential areas of improvement in how value frameworks assess benefits, costs, and 
other factors relevant to decision-making. Further research, testing, and discussion with 
stakeholders are needed to refine and enable such improvements for use in US health care systems. 
 
7. 7 Key Special Task Force Recommendations 
 
Our ISPOR Special Task Force on Value Assessment Frameworks makes the following key 
recommendations: 
 
Recommendation I:  Be explicit about decision context and perspective in value assessment 
frameworks. 
 
1. No single value assessment framework can simultaneously reflect multiple decision contexts and the 
perspectives of the patient, the health plan, or society as a whole.  Thus, it is important for any 
framework to clearly articulate the value construct it represents and the perspective and decision 
context in which it is to be used, and to be well validated and reliable within that construct and 
context. 
2. For societal and health plan resource allocation decisions, including coverage and reimbursement 
decisions, the perspective used should reflect, at a minimum, those who ultimately pay for care, 
including, for example, enrollees, employees, and taxpayers. 
3. Well-designed patient-level frameworks can help guide shared decision making for treatment 
choices among the clinically appropriate options that have been approved for coverage, so that 
patients and their providers can consider and weight factors most relevant to patient preferences 
and constraints.  
 
Recommendation II:  Base health plan coverage and reimbursement decisions on an evaluation of the 
incremental costs and benefits of healthcare technologies as is provided by cost-effectiveness 
analysis. 
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1. A central tenet in economics is to compare incremental costs and benefits in decision-making. Cost-
effectiveness analysis (CEA) and, in particular, cost-per-quality-adjusted life year (QALY) analysis 
have many demonstrated strengths ? and some recognized limitations; they are well established in 
health economics and utilized by decision makers in health systems worldwide.  
2. Value assessment frameworks that focus on health plan coverage and reimbursement decisions 
should consider cost-effectiveness analyses, as measured by cost per QALY, as a starting point to 
inform payer and policy maker deliberations. In many instances, the cost-per-QALY metric can serve 
well as the core component of these assessments. 
3. Elements of costs and benefits not normally included in CEA that affect individual well-being (such 
as severity of illness, equity, and risk protection) may be relevant for some health plan decisions; 
however, more research is needed on how best to measure and include them in decision making.  
 
Recommendation III:  Develop value thresholds to serve as one important input to help guide 
coverage and reimbursement decisions. 
 
1. Payers ? as agents for plan funders and patients ? should consider decision rules guided by what 
they consider good value for money given their opportunity cost and budget constraints. Consistent 
use of a value threshold, such as cost-per-QALY limits or ranges, with potential consideration of 
other elements, can help to achieve maximum health gain and individual well-being for the available 
resources. 
2. In the pluralistic US healthcare system, different health plans could use different thresholds or 
decision rules across or within plans for different types of patients, reflecting the differing 
generosity of their budgets and implying different levels of access to technologies.  Equity, severity 
of illness or disability, and other considerations may alter thresholds in certain situations. 
 
Recommendation IV:  Manage budget constraints and affordability based on cost-effectiveness 
principles. 
 
1. Budget impact analysis should not be an integral part of value assessment per se, but can play a role 
in addressing budget constraints and affordability 
2. Issues related to budget constraints and affordability of healthcare technology are most efficiently 
addressed in the short term by considering:  (a) the adjustment costs of reducing spending on, or 
replacing, existing technologies; (b) the health and cost impact of delaying or staging 
implementation of new technologies; and (c) the cost-effectiveness ratios of existing technologies 
relative to that of the innovation. 
3. Over time, the availability of cost-effective new technologies may alter the desired amount of health 
care spending. 
 
Recommendation V: Test and consider using structured deliberative processes for health plan 
coverage and reimbursement decisions 
 
1. No existing method completely or perfectly solves the problems of aggregating cost and benefit 
information across individuals to a population level for benefit plan decision making or of combining 
multiple elements of value into a single value metric for individuals.  Thus, pragmatic approaches are 
needed. 
2. Certain health care decisions, such as decisions to cover and pay for new technologies, can benefit 
from using deliberative processes that consider CEA along with other relevant decision criteria. 
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3. Deliberative processes for value assessment should consider using explicit frameworks such as 
augmented cost-effectiveness analysis (ACEA) and multi-criteria decision analysis (MCDA) that 
emphasize structure and transparency.  
4. MCDA models using individual patient-specific value weights could be developed to help patients 
choose among available medical interventions ? those chosen for coverage by their health plan ?
using both their own value weights and their out-of-pocket costs.  
 
Recommendation VI: Explore and test novel elements of benefit to improve value measures that 
reflect the perspectives of both plan members and patients. 
 
1. We encourage development of a more comprehensive economic evaluation that could include novel 
elements of value ? such as insurance value, real option value, value of hope, scientific spillovers, 
and others ? and could ultimately provide for more efficient resource allocation within the health 
sector and between health and non-health spending.  More research is needed on measuring the 
additional value provided by ? and the willingness to pay for ? these novel elements. 
2. More research is needed on MCDA development and use, particularly for generating value weights 
and thresholds, as compared to other approaches.  Alternative approaches for estimating value 
weights and thresholds in MCDA should be tested and compared both for methodological 
soundness and practical implementation factors (e.g., ease of use and reliability). Testing of MCDA 
models should include comparisons of their resource allocation implications with those of 
conventional or augmented CEA-based decision making as well as those of other decision 
approaches. 
3. Payers serve as agents for their plan members who both pay premiums and become patients.  
Obtaining input on the value of health benefits from members of health plans, informed by patient 
experience, is central to the validity of value measures.  
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